Anzeige
Mehr »
Login
Dienstag, 30.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
129 Leser
Artikel bewerten:
(0)

Hologic Announces Expiration of 6.25% Senior Notes Exchange Offer

BEDFORD, Mass., March 22, 2013 /PRNewswire/ --Hologic, Inc. (Hologic or the Company) (NASDAQ: HOLX), a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the expiration of its offer to exchange (the Exchange Offer) up to $1 billion aggregate principal amount of its 6.25% Senior Notes due 2020 which have been registered under the Securities Act of 1933, as amended (the Exchange Notes), for up to $1 billion of the Company's outstanding 6.25% Senior Notes due 2020, which were issued on August 1, 2012 in a private placement (the Old Notes). The Exchange Notes have substantially identical terms to the Old Notes. The Exchange Offer expired at 5:00 p.m. Eastern Time, on March 22, 2013.

Wells Fargo Bank, National Association, the exchange agent for the Exchange Offer, has advised that Old Notes in the aggregate principal amount of $994,130,000, representing 99.41% of the aggregate principal amount, were validly tendered and not validly withdrawn prior to the expiration of the Exchange Offer. The Company has accepted for exchange all of the validly tendered Old Notes, and expects to issue the Exchange Notes on or about March 27, 2013.

This press release is for informational purposes only and is neither an offer to exchange, nor a solicitation of an offer to sell, the Exchange Notes. The Exchange Offer was made pursuant to the prospectus dated February 21, 2013.

About Hologic, Inc.

Hologic, Inc. is a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems, and surgical products.The Company operates four core business units focused on diagnostics, breast health, GYN surgical and skeletal health.With a comprehensive suite of technologies and a robust research and development program, Hologic is committed to improving lives.The Company is headquartered in Massachusetts. For more information, visit www.hologic.com.

Contacts:

Deborah Gordon

David Cross


Vice President, Investor Relations

Vice President & Treasurer


(781) 999-7716

(781) 999-7789


deborah.gordon@hologic.com

david.cross@hologic.com





Al Kildani



Senior Director, Investor Relations



(858) 410-8653



al.kildani@hologic.com


SOURCE Hologic, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2013 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.